<DOC>
	<DOC>NCT00446485</DOC>
	<brief_summary>The purpose of the study is to determine weather Ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment</brief_summary>
	<brief_title>Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency</brief_title>
	<detailed_description>Inclusion criteria is cerebrovascular insufficiency MNSE&gt;20. 90 patients are divided into three groups randomly. First group is being administered 120 mg ginkgo biloba extract, second group 60 mg of the extract and the third group has being administered placebo during the period of 6 months. Methods used for evaluation are SCAG, MMSE, MDRS, VFT, CGI, TCD and color Doppler of carotid arteries. Methods used for follow up safety include: routine blood tests, biochemical tests, neurologic and physical examination, vital signs and ECG.</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<criteria>cerebrovascular insufficiency and mild cognitive disorder (MMSE=2028) pregnancy cognitive disorder caused by psychological, metabolic endocrine nutritional and heart disorder alcohol or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>ginkgo biloba</keyword>
	<keyword>cerebrovascular insufficiency</keyword>
	<keyword>mild cognitive impairment</keyword>
	<keyword>concentration impairment</keyword>
</DOC>